Celltrion Holds Science & Innovation Day 2026

Focus Shifts to 'New Drug Valuation'
Among Analysts and Institutional Investors

Celltrion announced on the 27th that it held the 'Celltrion Science & Innovation Day 2026 (CSID)' at Conrad Seoul Hotel in Yeouido, Yeongdeungpo-gu, Seoul, on the 26th.

This year's CSID, held under the theme "Global New Drugs Enabled by Open Innovation," was organized to present Celltrion's blueprint for new drug development and its differentiated development capabilities to the market, and to deliver its ambition to become a truly global new drug company. In addition, the event showcased the specialized strengths of companies collaborating with Celltrion through open innovation.

In particular, while last year's event was limited to analysts from the domestic and international securities industry, this year the audience was expanded to include institutional investors, venture capitalists (VCs), and research institutes, providing a broader understanding of the value of Celltrion's new drug pipeline.

At the event, Kwon Kisung, Head of R&D at Celltrion, delivered a presentation on "Celltrion's New Drug Vision," introducing Celltrion's next-generation antibody development strategies, technological differentiation, and commercialization plans. He also explained that Celltrion is combining its accumulated development competencies with innovative technologies from external partners to build a more competitive new drug development model.

During the following session, CEOs of biotech venture companies collaborating with Celltrion gave presentations on topics including ▲Advancing Next-Generation Autoimmune Therapeutics (Shin Minjae, CEO of Kaijin) ▲Next Leap in Immuno-oncology (Kim Maengseop, CEO of MustBio) ▲Beyond Spatial Biology (Lee Daeseung, CEO of Portrait) ▲Galux Design—AI as an Integrative and Convergent Tool for New Drug Development (Seok Chaok, CEO of Galux).

Subsequently, Jang Soyong, Head of New Business at Celltrion, introduced Celltrion's open innovation roadmap and various collaboration cases that are expanding the new drug development ecosystem. Currently, Celltrion operates a total of six open innovation programs with public institutions, universities, and others across Korea, and is planning to further expand these programs into global markets including the United States, Japan, and China.

Finally, Celltrion CEO Seo Jinseok took the stage to introduce the overall new drug portfolio and present the blueprint for implementing open innovation. Seo explained that Celltrion is currently developing new drugs to address global unmet needs in various modality areas—including antibody-drug conjugates (ADCs), multi-antibodies, novel antibodies and fusion proteins, peptides, and microbiomes. He emphasized that, based on Celltrion's end-to-end bio-business competency, the company aims to generate global success stories in new drugs through open innovation.

The event is evaluated as having elevated market perception of Celltrion's new drug development capabilities and increased investor interest. Jeong Isu, a researcher at IBK Investment & Securities who attended the event, commented, "It was a valuable opportunity to concretely confirm the status and technical differentiation of Celltrion's new drug pipeline," and added, "It was especially meaningful in terms of deepening understanding of the technologies and pipeline value secured through open innovation."

Buoyed by this positive response, the company plans to make CSID, first held last year, a regular event to share Celltrion's R&D capabilities and philosophy as its representative conference.

CEO Seo Jinseok said, "Through this event, we have communicated the competitiveness of Celltrion's new drug pipeline more concretely and clearly to the market," and added, "We will continue to gradually announce new drug development achievements, maximize corporate value through this, and take a leap forward as a truly global new drug company."

This content was produced with the assistance of AI translation services.